Okyo Pharma Announces Safety Data Profile For Ongoing OK-101 Phase 2 Trial For Dry Eye Disease; Patients Continue In The Study, Double-blind Procedures Are Still In Effect Until All Patients Complete The 12-week Dosing Duration; Topline Data In December
Portfolio Pulse from Benzinga Newsdesk
Okyo Pharma has announced the safety data profile for its ongoing OK-101 Phase 2 trial for dry eye disease. The patients continue in the study and double-blind procedures are still in effect until all patients complete the 12-week dosing duration. The company expects to release topline data in December.
October 05, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Okyo Pharma's ongoing Phase 2 trial for dry eye disease treatment OK-101 continues with no safety concerns. Topline data is expected in December, which could impact the company's stock.
The news directly pertains to Okyo Pharma and its ongoing clinical trial. The release of topline data in December could potentially impact the company's stock price, depending on the results. However, as the data is not yet available, the short-term impact is neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100